PEDRO ROMAGUERA: Open Payments
NPI 1659303857 · METAIRIE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$625 in 23 payments from 13 companies in 2025. Trend: 2023 $1,592 · 2024 $1,021 · 2025 $625
Food & beverage: $625
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $162 |
| Vanda Pharmaceuticals Inc. | 3 | $72 |
| Aimmune Therapeutics, Inc. | 3 | $66 |
| ABBVIE INC. | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Dexcom, Inc. | 2 | $42 |
| Alpha Cognition USA, Inc. | 1 | $41 |
| Lundbeck LLC | 1 | $25 |
| Astellas Pharma US Inc | 1 | $25 |
| Lilly USA, LLC | 1 | $23 |
Products named: BREZTRI, REXULTI, FANAPT, ZENPEP, Dexcom G6 Transmitter, Zunveyl, LINZESS, FARXIGA.
Industry payments across LA — which companies pay providers there.
